Imagine your lungs have a plumbing problem where the pipes are blocked, making the heart work too hard to push blood through. Current medicines only mask the symptoms, like putting a bandage on a leak. This project created a drug that targets the actual root cause of the blockage to fix the system in both the heart and lungs.
Current standard-of-care drugs for pulmonary arterial hypertension only treat symptoms rather than the root cause and cause serious side-effects. This leaves a massive gap in the market for a disease-modifying treatment.
A capsule formulation of the drug NTP42 for home use and the necessary safety and manufacturing data required for Phase II clinical trials.
If you are a pharmaceutical enterprise dealing with a lack of curative treatments for PAH — this project developed NTP42 that blocks the thromboxane receptor. This allows for a licensing deal to bring a disease-modifying drug to market.
If you are a biotech firm dealing with the challenge of moving from liquid formulas to patient-friendly dosing — this project developed a capsule form of NTP42. This enables patients to take the medication at home in non-clinical settings.
If you are a clinic dealing with patients who suffer from severe side-effects of standard-of-care drugs — this project developed a drug that treats clinical hallmarks in both lungs and heart. This offers a more effective option for devastating cardiopulmonary diseases.
The objective states that sales are expected to exceed $1B at 5 years post-launch.
ATXA intends to secure a licensing deal with a pharmaceutical company to accelerate the drug to market and receive royalty returns.
The project has moved past Phase I trials in healthy men and is preparing for a Phase II clinical trial in PAH patients.
The project focused on pre-trial work for regulatory approval, including drug manufacture, safety studies, and a bridging clinical trial for the capsule form.
The project period was from 2023-01-01 to 2023-12-31.
The project is led by a single SME, ATXA Therapeutics Ltd, based in Ireland. With a 100% industry ratio and no university or research partners, the consortium is lean and focused entirely on commercial translation and clinical acceleration.
Contact ATXA Therapeutics Ltd in Ireland regarding NTP42 licensing
Contact us to identify potential pharma partners for NTP42 licensing.
